ECSP22055210A - Triterpenoides sint?ticos con sustituyentes a base de nitr?geno en c-17 y m?todos de uso de los mismos - Google Patents

Triterpenoides sint?ticos con sustituyentes a base de nitr?geno en c-17 y m?todos de uso de los mismos

Info

Publication number
ECSP22055210A
ECSP22055210A ECSENADI202255210A ECDI202255210A ECSP22055210A EC SP22055210 A ECSP22055210 A EC SP22055210A EC SENADI202255210 A ECSENADI202255210 A EC SENADI202255210A EC DI202255210 A ECDI202255210 A EC DI202255210A EC SP22055210 A ECSP22055210 A EC SP22055210A
Authority
EC
Ecuador
Prior art keywords
nitrogen
methods
same
based substituents
synthetic triterpenoids
Prior art date
Application number
ECSENADI202255210A
Other languages
English (en)
Inventor
Christopher Bender
Lloyd Simons
Ingo Janser
Melean Visnick
Xin Jiang
Ha Do
Haizhou Sun
Heinrich Schostarez
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of ECSP22055210A publication Critical patent/ECSP22055210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta solicitud reivindica el beneficio de prioridad para las Solicitudes Provisionales de Estados Unidos Nos. 63/198.310, presentada el 9 de octubre de 2020, 62/950.927, presentada el 19 de diciembre de 2019, y 62/950.919, presentada el 19 de diciembre de 2019, cuyos contenidos completos se incorporan por la presente como referencia.
ECSENADI202255210A 2019-12-19 2022-07-15 Triterpenoides sint?ticos con sustituyentes a base de nitr?geno en c-17 y m?todos de uso de los mismos ECSP22055210A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950927P 2019-12-19 2019-12-19
US201962950919P 2019-12-19 2019-12-19
US202063198310P 2020-10-09 2020-10-09

Publications (1)

Publication Number Publication Date
ECSP22055210A true ECSP22055210A (es) 2022-08-31

Family

ID=74554207

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202255210A ECSP22055210A (es) 2019-12-19 2022-07-15 Triterpenoides sint?ticos con sustituyentes a base de nitr?geno en c-17 y m?todos de uso de los mismos

Country Status (18)

Country Link
US (1) US20230111914A1 (es)
EP (1) EP4077347A1 (es)
JP (1) JP2023507402A (es)
KR (1) KR20220116209A (es)
CN (1) CN115087660A (es)
AU (1) AU2020405181A1 (es)
BR (1) BR112022011919A2 (es)
CA (1) CA3159778A1 (es)
CL (1) CL2022001661A1 (es)
CO (1) CO2022010070A2 (es)
CR (1) CR20220345A (es)
DO (1) DOP2022000127A (es)
EC (1) ECSP22055210A (es)
IL (1) IL293876A (es)
MX (1) MX2022007595A (es)
PE (1) PE20221662A1 (es)
TW (1) TW202135828A (es)
WO (1) WO2021127480A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259155A1 (en) * 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588710A (en) * 2008-04-18 2012-12-21 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CN104250280A (zh) * 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
WO2009129545A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
UY35534A (es) * 2013-04-24 2014-10-31 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
WO2020068689A1 (en) * 2018-09-28 2020-04-02 Fronthera U.S. Pharmaceuticals Llc Terpinoid derivatives and uses thereof

Also Published As

Publication number Publication date
CN115087660A (zh) 2022-09-20
CO2022010070A2 (es) 2022-08-09
JP2023507402A (ja) 2023-02-22
AU2020405181A1 (en) 2022-07-14
BR112022011919A2 (pt) 2022-09-06
PE20221662A1 (es) 2022-10-26
WO2021127480A1 (en) 2021-06-24
US20230111914A1 (en) 2023-04-13
MX2022007595A (es) 2022-07-19
DOP2022000127A (es) 2022-09-15
IL293876A (en) 2022-08-01
EP4077347A1 (en) 2022-10-26
KR20220116209A (ko) 2022-08-22
CR20220345A (es) 2023-01-12
TW202135828A (zh) 2021-10-01
CL2022001661A1 (es) 2023-01-27
CA3159778A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CO2018012996A2 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CO2019002975A2 (es) Compuestos de tetraciclina y métodos de uso de los mismos
ECSP18038868A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
MX2020003125A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
UY34669A (es) COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
DOP2020000119A (es) Conjugados anticuerpo anti-cd40-fármaco
UY38391A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anti hla-g
ECSP18049762A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
ECSP20013332A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
UY34668A (es) COMPUESTOS EN BASE A PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
ECSP20013337A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
CL2021001308A1 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteína de los mismos para su uso como agonistas de lxr.
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
ECSP22055210A (es) Triterpenoides sint?ticos con sustituyentes a base de nitr?geno en c-17 y m?todos de uso de los mismos
ES1257967Y (es) Dispositivo de accionamiento, sincrono, paralelo y de multiples puntos, y aplicacion para el mismo
CL2019001804A1 (es) Activador de nrf2.
CL2019003557A1 (es) Anticuerpos anti-trkb.
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
MX2020004178A (es) Composiciones de cannabidiol y quitosano y métodos de uso de éstas.